Intensive treatment most needed early in MG course: Study
Many adults with myasthenia gravis (MG) need intensive treatment in the first year after diagnosis, with younger patients and…
Articles by Margarida Maia, PhD
Healthcare costs for MG high in 3 Nordic countries: Study
The healthcare costs of myasthenia gravis (MG) are high, according to a study from Denmark, Finland, and Sweden, and…
Nipocalimab safely eases gMG symptoms in teens: Vibrance trial
Johnson & Johnson’s nipocalimab appears to be safe and to ease symptoms of generalized myasthenia gravis (gMG) in…
Vyvgart Hytrulo as effective as Vyvgart at reducing IgG levels
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase), an approved therapy for generalized myasthenia gravis (gMG) that’s injected under the…
Soliris sustains clinical benefit for MG in real-world setting
Soliris (eculizumab) effectively eased symptoms and reduced the need for other medications in adults with myasthenia gravis (MG)…
Harbour BioMed resubmits request for batoclimab approval in China
Harbour BioMed has submitted a new, revised version of a biologics license application (BLA) to China’s regulatory agency requesting…
More frequent Vyvgart dosing may be needed in real world: Study
Patients who received Vyvgart (efgartigimod alfa) as part of an expanded access program required more frequent dosing to treat…
Acid from gut bacteria may become potential treatments for MG: Study
Butyric acid from gut bacteria, or supplementation with its salt form butyrate, could become potential treatments for myasthenia gravis…
AAN 2024: Many Vyvgart-treated patients have few, if any, symptoms
Many of the adults with generalized myasthenia gravis (gMG) who took part in ADAPT, a Phase 3 clinical study…
AAN 2024: Benefits of Ultomiris sustained for more than 3 years
Ultomiris (ravulizumab) continues to be well tolerated and to keep symptoms of generalized myasthenia gravis (gMG) under control…